Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in around 15–20% of breast cancer patients and expressed to a lesser degree in a large fraction of the remaining breast cancers [1,2,3]. This evidence concerns the gene ERBB2 and breast cancer.